Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 11/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.78 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455323 | 0.91 | GAA (0.74) | IDO1MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL1642748 | 0.91 | IDO1 (0.67) | IDO1MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL455272 | 0.89 | IDO1 (0.64) | IDO1MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL455548 | 0.89 | IDO1 (1.00) | IDO1MAPTKDM4EGAAMEN1 | |
| SCHEMBL5435931 | 0.89 | IDO1 (1.00) | IDO1MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL3860141 | 0.89 | KDM4E (1.00) | IDO1MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL9036606 | 0.89 | IDO1 (1.00) | IDO1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL455167 | 0.87 | ALDH1A1 (0.73) | IDO1MAPTKDM4EGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL9004637 | 0.87 | IDO1 (0.96) | IDO1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL28525082 | 0.85 | ALDH1A1 (0.70) | IDO1MAPTKDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669505-B | Preparation method and application of red fluorescence enhanced probe for detecting mercury ions | 福建师范大学 | 2022-07-12 | — | — | CN | disclosed |
| CN-110669505-A | Preparation method and application of red fluorescence enhanced probe for detecting mercury ions | 福建师范大学 | 2020-01-10 | — | — | CN | disclosed |
| US-8475765-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| EP-2143736-B1 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DE GMBH (DE) | 2012-11-07 | — | — | EP | disclosed |
| US-8299285-B2 | Compounds for imaging and therapy | ISIS INNOVATION LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299285-B2 | Compounds for imaging and therapy | ISIS INNOVATION LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| WO-2012033601-A1 | THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20120046240-A9 | Method of Producing Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046240-A9 | Method of Producing Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2316850-A2 | HASylated polypeptides, especially HASylated erythropoietin | Fresenius Kabi Deutschland GmbH (DE) | 2011-05-04 | — | — | EP | disclosed |
| EP-2272865-A2 | Method of producing hydroxyalkyl starch derivatives | Fresenius Kabi Deutschland GmbH (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100317609-A1 | Method of Producing Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317609-A1 | Method of Producing Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7815893-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-7815893-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| EP-2154160-A1 | Hydroxyalkyl starch derivatives | Fresenius Kabi Deutschland GmbH (DE) | 2010-02-17 | — | — | EP | disclosed |
| EP-2143736-A1 | Hydroxyalkyl starch derivatives | Fresenius Kabi Deutschland GmbH (DE) | 2010-01-13 | — | — | EP | disclosed |
| EP-2017287-A2 | Method of producing hydroxyalkyl starch derivatives | Fresenius Kabi Deutschland GmbH (DE) | 2009-01-21 | — | — | EP | disclosed |
| EP-1398327-B1 | Method of producing hydroxyalkyl starch derivatives | FRESENIUS KABI DE GMBH (DE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007003944-A2 | COMPOUNDS FOR IMAGING AND THERAPY | ISIS INNOVATION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046240-A9 | Method of Producing Hydroxyalkyl Starch Derivatives | HACL2, HAAO, LIPA | IDO1 1632/4885MAPT 4440/4885KDM4E 3187/4885 |
| US-20100317609-A1 | Method of Producing Hydroxyalkyl Starch Derivatives | HACL2, HAAO, LIPA | IDO1 1632/4885MAPT 4440/4885KDM4E 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.